Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.
Doi H, Matsuo Y, Kishi N, Ogura M, Mitsuyoshi T, Ueki N, Ueki K, Fujii K, Sakamoto M, Atsuta T, Katagiri T, Sakamoto T, Narabayashi M, Ohtsu S, Fujishiro S, Kishi T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG).
Doi H, et al. Among authors: kishi n.
Target Oncol. 2025 Jan;20(1):161-169. doi: 10.1007/s11523-024-01105-5. Epub 2024 Nov 7.
Target Oncol. 2025.
PMID: 39511126